Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

1.695 -0.315 (-15.67%)
Streaming Delayed Price Updated: 9:48 AM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Coherus Oncology, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Mark Cuban's Pharmacy Company Lands Deal With Top 10 US Retailer: Here Are The Details ↗
Since launching the Mark Cuban Cost Plus Drug Company in 2022, entrepreneur and NBA team owner Mark Cuban has been on a mission to lower the cost of medicines for consumers. 
Via Benzinga
News headline image
10 Analysts Have This to Say About Coherus BioSciences ↗
 
Via Benzinga
News headline image
Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY™
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Cramer Is Still Bullish On AI Company Up 155% YTD: 'I Remain A Buyer' ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he's surprised by the slow progress of Rambus Inc. (NASDAQ: RMBS). 
Via Benzinga
News headline image
Health Care Company Coherus BioSciences Announces Merger With Surface Oncology ↗
 
Via Benzinga
News headline image
Analyst Expectations for Coherus BioSciences's Future ↗
 
Via Benzinga
News headline image
Coherus' Toripalimab/Chemo Combo Cuts Death Risk By 37% In Nasopharyngeal Cancer Patients ↗
 
Via Benzinga
News headline image
Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S.
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Synergy Of Coherus And Surface Oncology: Analyst Forecasts $50M Savings And 2024 Profitability ↗
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating on the shares of Coherus BioSciences, Inc. 
Via Benzinga
News headline image
Nasdaq Down 80 Points; US Consumer Sentiment Surges To 4-Month High In June ↗
U.S. stocks traded lower toward the end of trading, with Nasdaq Compsoite dropping around 80 points on Friday. The Dow traded down 0.24% to 34,324.18 while the NASDAQ fell 0.59% to 13,701.06. The S&P... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Is AbbVie Stock Trading Down Today? ↗
AbbVie Inc. (NYSE: ABBV) shares are trading lower Thursday after Coherus BioSciences Inc. 
Via Benzinga
News headline image
Looking Into Coherus BioSciences's Return On Capital Employed ↗
 
Via Benzinga
News headline image
6 Analysts Have This to Say About Coherus BioSciences ↗
 
Via Benzinga
News headline image
Stocks Headed For Strong Weekly Wins ↗
Stocks are struggling for direction midday, but all three major indexes are on track for strong weekly gains. 
Via Talk Markets
News headline image
Why Squarespace Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Oncorus, Inc. (NASDAQ: ONCR) shares surged 258% to $0.2781. 
Via Benzinga
News headline image
Crude Oil Rises; Adobe Posts Upbeat Results ↗
U.S. stocks traded slightly higher midway through trading, with Dow Jones gaining around 20 points on Friday. The Dow traded up 0.06% to 34,428.13 while the NASDAQ rose 0.05% to 13,789.23. The S&P 500,... 
Via Benzinga
News headline image
Coherus BioSciences, MicroVision, Millicom And Other Big Stocks Moving Lower On Friday ↗
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Friday. Here are some big stocks recording losses in today’s session. Coherus BioSciences, Inc. (NASDAQ: CHRS) tumbled 16.8%... 
Via Benzinga
News headline image
US Stocks Mixed; Dow Gains 50 Points ↗
U.S. stocks traded mixed this morning, with Dow Jones gaining around 50 points on Friday. Following the market opening Friday, the Dow traded up 0.16% to 34,464.01 while the NASDAQ fell 0.14% to... 
Via Benzinga
News headline image
This Biotech Is About to Eat AbbVie's Market Share, but Is It a Buy? ↗
Coherus' biosimilar to Humira could catapult the company to success. 
Via The Motley Fool
News headline image
Coherus BioSciences Acquires Small Immuno-Oncology Player Surface Oncology For $40M ↗
Coherus BioSciences Inc (NASDAQ: CHRS) has agreed to acquire Surface Oncology Inc (NASDAQ: SURF), a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that  
Via Benzinga
News headline image
Coherus to Acquire Surface Oncology
From Surface Oncology, Inc.
Via GlobeNewswire
News headline image
AbbVie vs Coherus: Dispute Emerges over Upcoming Launch of Low-Cost Biosimilar, Yusimry ↗
AbbVie Inc (NYSE: ABBV) has challenged Coherus BioSciences Inc (NASDAQ: CHRS), alleging Coherus breached its settlement and license agreement after it announced its plans to launch Yusimry, a... 
Via Benzinga
News headline image
Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Biotech Alert: Searches Spiking For These Stocks Today - Friday, June 2 ↗
Various names in the biotech sector are seeing a substantial increase in search activity today. Such names include the likes of Akebia Therapeautics, Corvus Pharmaceuticals, and Mirati Therapeutics. 
Via Talk Markets
News headline image
Mark Cuban Helping Lower Cost Of Bestselling Humira With Cost Plus Drug Company: 'The Game Just Changed' ↗
One of the bestselling medical drugs of all time has come off patent. The result could mean lower costs for those who need the drug as a treatment option. Enter Mark Cuban and his Cost Plus Drug... 
Via Benzinga
News headline image
Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY™ (adalimumab-aqvh) Launching in July 2023
List price of $995 per carton for two 40 mg/0.8 mL autoinjectors 
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Top 5 Health Care Stocks That Could Blast Off In May ↗
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
News headline image
Coherus Announces U.S. Launch of UDENYCA® Autoinjector
From Coherus BioSciences, Inc.
Via GlobeNewswire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.